arrow
J

Josep V. Forment

astrazeneca
H指数:27
被引数:3,900

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Micronucleus quantification from whole-slide haematology images using AI serves as a translatable pharmacodynamic biomarker for DNA damage response inhibitors

利用AI对全玻片血液学图像中的微核进行定量分析,可作为DNA损伤反应抑制剂的可转化药效学生物标志物。

2026-02-280
OAAI
Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells

PARP1捕获作为BRCA突变癌细胞中PARP抑制剂疗效驱动因素的遗传证据

2025-12-110
PRE
Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair

雄激素受体抑制在前列腺癌模型中扩展了PARP抑制剂的活性,超越了BRCA突变和同源重组修复缺陷。

2025-12-010
OAAI
Base editing screens define the genetic landscape of cancer drug resistance mechanisms
2024-10-181
OAAI
Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma
2024-06-061
OAAI
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours
2024-05-244
OAAI
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells

MND1和PSMC3IP控制有丝分裂细胞的PARP抑制剂敏感性

2023-05-013
OA
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

用于鉴定同源重组缺陷肿瘤和患者分层的RAD51测试的临床前体内验证

2022-02-1645
OA
Reversing PARP inhibitor resistance by targeting the replication stress response
2019-07-010
PRE